Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 10/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422047 | 0.87 | ADRA1D (0.35) | ADRA1DADRA1AADRA1BDRD3ADRB2 | |
| SCHEMBL2547252 | 0.86 | ADRA1D (0.37) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL2548785 | 0.84 | SCN1A (0.40) | SCN1ASCN2ASCN3ADRD3HRH3 | |
| SCHEMBL526254 | 0.82 | NOTUM (0.38) | ADRA1DADRA1AADRA1BHRH3HTR1A | |
| SCHEMBL18902664 | 0.82 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BDRD3ADRB2 | |
| SCHEMBL17516018 | 0.81 | ADRA1D (0.32) | ADRA1DADRA1AADRA1B | |
| SCHEMBL16166306 | 0.80 | ADRA1D (0.31) | ADRA1DADRA1AADRA1B | |
| SCHEMBL16166538 | 0.80 | ADRA1D (0.33) | ADRA1DADRA1AADRA1BDRD3ADRB2 | |
| SCHEMBL2554973 | 0.80 | ADRA1D (0.37) | ADRA1DADRA1AADRA1BDRD3ADRB2 | |
| SCHEMBL16166283 | 0.78 | ADRA1D (0.37) | ADRA1DADRA1AADRA1BBCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012131710-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES | PANACEA BIOTEC LTD (IN) | 2012-10-04 | — | — | WO | claimed |
| US-9938239-B2 | Method for preparing silodosin | SANDOZ AG (CH) | 2018-04-10 | — | — | US | disclosed |
| EP-2768806-B1 | METHOD FOR PREPARING SILODOSIN | SANDOZ AG (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20160176818-A1 | Method For Preparing Silodosin | SANDOZ AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20150038727-A1 | METHOD FOR PREPARING SILODOSIN | SANDOZ AG (CH) | 2015-02-05 | — | — | US | disclosed |
| WO-2015010594-A1 | INDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 中国科学院上海药物研究所 (CN) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014190942-A1 | INDOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 (CN) | 2014-12-04 | — | — | WO | disclosed |
| WO-2012147107-A2 | NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION | MSN LABORATORIES LIMITED (IN) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012131710-A2 | NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES | PANACEA BIOTEC LTD (IN) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011124704-A1 | PROCESS FOR PREPARING AN INTERMEDIATE FOR SILODOSIN | RATIOPHARM GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176818-A1 | Method For Preparing Silodosin | RCC2, RIOX2, CYP51A1 | ADRA1D 607/4885ADRA1A 1021/4885ADRA1B 1304/4885 |
| US-20150038727-A1 | METHOD FOR PREPARING SILODOSIN | RCC2, RIOX2, CYP51A1 | ADRA1D 607/4885ADRA1A 1021/4885ADRA1B 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.